Icagen Inc. said it has completed its acquisition of Sanofi's research facility in Oro Valley, near Tucson, enabling Icagen to enhance its expertise as a specialized pharmaceutical services company.

The acquisition includes an agreement between Icagen and Sanofi for a multiyear services contract.

"The acquisition of Sanofi's West Coast ultra high throughput screening biology and chemistry capabilities complements our scientific expertise enabling us to offer a broad range of integrated drug discovery services in a growing market," Icagen President and CEO Richard Cunningham said.

Scientists at the Oro Valley site bring a high level of proficiency in synthetic and computational chemistry and additional capabilities for rare disease biology and phenotypic screening, Douglas Krafte, chief scientific officer at Icagen, said.